[Efficacy of prophylactic intravesical mitomycin C in patients with non-muscle-invasive bladder cancer].

Abstract

Intravesical chemotherapy is beneficial for patients with non-muscle-invasive bladder cancer (NMIBC), but optimal drug and regimen selection can be controversial. Mitomycin C (MMC) is commonly used as adjuvant treatment for NMIBC. We retrospectively evaluated the outcomes of 73 patients with NMIBC who were treated with weekly doses of low-dose MMC (20 mg ; n=28 ; 38.4%) or high-dose MMC (40 mg ; n=45 ; 61.6%) for 6 weeks each, at our hospital between 2001 and 2010. Treatment outcomes were examined by Kaplan‒Meier analysis with log-rank tests. Patients in the high-dose group showed greater recurrent-free survival (61.3%) at 2 years than did patients in the low-dose group (32.6%) (P<0.05). We also found that a single early dose of pirarubicin following transurethral resection of bladder tumor improved MMC efficacy in the high-dose group. The high-dose group had a somewhat higher incidence of dysuria, urinary frequency and drug eruption, but the difference was not significant.

• Authors: Haruyuki Ohsugi, Yuki Kitamura, Yumi Manabe, Norihiko Masuda, Haruki Ito, Mutsuki Mishina, Hiroshi Okuno
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 60 Issue 8 Pg. 375-9 (Aug 2014) ISSN: 0018-1994 [Print] Japan
• PMID: 25179987 (Publication Type: English Abstract, Journal Article)

Chemical References

• Mitomycin

Topics

• Administration, Intravesical
• Aged
• Aged, 80 and over
• Female
• Humans
• Male
• Middle Aged
• Mitomycin (therapeutic use)
• Neoplasm Invasiveness
• Retrospective Studies
• Secondary Prevention
• Treatment Outcome
• Urinary Bladder Neoplasms (drug therapy, pathology)